| General information | Literature | Expression | Regulation | Mutation | Homolog | Interaction |
Basic Information | |
|---|---|
Gene ID | 330 |
Name | BIRC3 |
Synonymous | baculoviral IAP repeat containing 3;BIRC3;baculoviral IAP repeat containing 3 |
Definition | IAP homolog C|IAP-1|RING finger protein 49|TNFR2-TRAF signaling complex protein|TNFR2-TRAF-signaling complex protein 1|apoptosis inhibitor 2|baculoviral IAP repeat-containing 3|baculoviral IAP repeat-containing protein 3|inhibitor of apoptosis protein 1|m |
Position | 11q22 |
Gene type | protein-coding |
Title | Abstract |
| liver cancer | OBJECTIVE: To study the expression of cellular inhibitor of apoptosis protein-2 (C-IAP2) mRNA and protein in hepatocellular carcinoma (HCC) and its relationship with the clinical outcomes. METHODS: Quantitative PCR and immunohistochemical staining were used to detect the expression of C-IAP2 mRNA and protein in the tumor tissues and corresponding adjacent non-cancerous tissues from HCC patients. RESULTS: The expression of C-IAP2 mRNA in HCC tissues was 2.70 folds higher than that in the non-cancerous tissues (P<0.001). The expression rate of C-IAP2 protein in HCC tissues was 70.8%, significantly higher than that in the non-cancerous tissues (27.8%, P=0.001). The expression of C-IAP2 mRNA and protein was associated with the tumor emboli, lymph node metastasis, AFP level, histological differentiation, TNM stage, postoperative recurrence and metastasis (P<0.05), but not with the patients' gender, age, HbsAg positivity, number of tumors, cirrhosis or the presence of tumor encapsulation (P>0.05). CONCLUSION: The expression of C-IAP2 in HCC is associated with tumor recurrence and metastasis, and can be a biological marker for prognostic evaluation of HCC. |